Is Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) Eliquis really safer than its competitors? A recent analysis of FDA adverse events reports suggested that it is ...
If you've watched television lately, you know that Pfizer ($PFE) and Bristol-Myers ($BMY) have been spending a lot of money on advertising to back their new ...
It might be more than a year from now, but litigation centered on the blood thinner Xarelto could eventually come to trial in Philadelphia courtrooms – and one attorney says the thousands of cases ...
MONDAY, Oct. 3, 2016 -- The blood thinner Xarelto may pose a slightly greater risk of serious bleeding than Pradaxa in patients with the abnormal heartbeat known as atrial fibrillation, new research ...
NEW YORK, June 14 (Reuters) - For millions of heart patients, a pair of new blood thinners have been heralded as the first replacements in 60 years for warfarin, a pill whose hardships and risks have ...
Grenoble, France - With the long-awaited advents of rivaroxaban (Xarelto, Bayer/Johnson & Johnson), apixaban (Eliquis, Pfizer/Bristol-Myers Squibb), and dabigatran (Pradaxa, Boehringer Ingelheim) as ...
Johnson & Johnson and Bayer said Monday that they had agreed to pay $775 million to settle about 25,000 lawsuits involving the blood thinner Xarelto, which they jointly sell. The settlement, which ...
Factor Xa-inhibiting anticoagulants like Johnson & Johnson's Xarelto are rapidly winning prescriptions away from warfarin and Boehringer's Pradaxa. Warfarin has long been doctor's go-to medicine for ...
NEW YORK (Reuters) - For millions of heart patients, a pair of new blood thinners have been heralded as the first replacements in 60 years for warfarin, a pill whose hardships and risks have deterred ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback